IN THE NEWS
IN THE NEWS
Houston Business Journal, December 2015
Xconomy, September 2015
BioNewsTexas, September 2015
Houston Business Journal, September 2015
ACF PHARMACEUTICALS is developing small molecule therapeutics that target novel pathways in a variety of inflammation-induced cancers including melanoma, inflammatory breast cancer, colon cancer, and pancreatic cancer. ACF is currently creating value by continuing to synthesize new compounds and testing these compounds for activity in cancer models to expand our IP portfolio.
ACF is actively developing therapeutics that target the inflammatory pathway downstream of COX1/2 to reduce unwanted side effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs) and specific COX inhibitors for a variety of inflammation-induced diseases. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most successful drugs in history. These drugs constitute a >13 billion dollar per year combined market. They are widely used to treat inflammation-induced diseases and target cyclooxygenase (COX) as the rate limiting step in the synthesis of pro-inflammatory and pro-oncogenic prostaglandin E2 (PGE2) lipids. However, long-term therapeutic use of these drugs is associated with severe gastrointestinal, renal, and cardiovascular side effects.
Inflammatory-induced diseases including melanoma, inflammatory breast cancer, colon cancer, and pancreatic cancer.